Antineoplastic agents. 565. Synthesis of combretastatin D-2 phosphate and dihydro-combretastatin D-2
- PMID: 20161135
- PMCID: PMC2729559
- DOI: 10.1021/np800635h
Antineoplastic agents. 565. Synthesis of combretastatin D-2 phosphate and dihydro-combretastatin D-2
Abstract
A modified synthetic route to combretastatin D-2 (5) was devised in order to further evaluate its biological activity, for its conversion to phosphate prodrugs (25-28), and as a route to obtaining dihydro-combretastatin D-2 (42). A parallel first total synthesis of dihydro-combretastatin D-2 was completed, proceeding from a saturated 3-phenylpropionic ester intermediate via the Ullmann biaryl ether reaction (39-41). In contrast to the cancer cell growth inhibitory activity exhibited by combretastatin D-2, relatively minor structural modifications (41, 42) caused elimination of those properties.
Figures
References
-
-
For the preceding contribution (AA 564) refer to: Monk KA, Siles R, Hadimani MB, Mugabe BE, Ackley JF, Studerus SW, Edvardsen K, Trawick ML, Garner CM, Rhodes MR, Pettit GR, Pinney KG. Bioorg Med Chem. 2006;14:3231–3244.
-
-
- Pinney KG, Jelinek C, Edvardsen K, Chaplin DJ, Pettit GR. In: Anticancer Agents from Natural Products. Cragg GM, Kingston DGI, Newman DJ, editors. Chapter 3. CRC Press; Boca Raton, FL: 2005. pp. 23–46.
-
- Pettit GR, Cragg GM, Herald DL, Schmidt JM, Lohavani-jaya P. Can J Chem. 1982;60:1374–1376.
-
- Pettit GR, Singh SB, Cragg GM. J Org Chem. 1985;50:3404–3406.
-
- Pettit GR, Singh SB, Niven ML, Hamel E, Schmidt JM. J Nat Prod. 1987;50:119–131. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
